ArticleInternational journal of medical sciences2026
Stem cells ameliorate neurotrauma-induced visual disturbances and retinal degeneration via broad normalization of β-catenin-related signaling.
Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traumatic brain injury (TBI) is associated with visual dysfunction and retinal degeneration, but the underlying mechanisms and therapeutic options remain limited. Mesenchymal stem cells (MSCs) have shown neuroprotective effects in various central nervous system injuries, including optic neuropathies. Objective: To investigate the protective effects and mechanisms of MSC therapy in TBI-induced retinal degeneration using Methods: Repeated mild TBI was induced in adult male Wistar rats by lateral fluid percussion. On day 3 post-injury, rats received intravenous MSCs (4 × 10⁶ cells/ml/kg) or saline. Visual and neurological functions were assessed using the visual cliff test and modified neurological severity score (mNSS). Thirty-five days after TBI, retinal tissues were collected for histological and immunofluorescence analysis. Results: TBI caused visual deficits, brain injury, retinal ganglion cell loss, thinning of the ganglion cell complex, increased neuronal apoptosis, and decreased β-catenin-positive neurons. Conclusion: MSC therapy mitigates TBI-induced visual dysfunction and retinal degeneration, in association with β-catenin-related neuroprotective signaling, and may represent a promising strategy for treating TBI-related visual and retinal injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.